NASDAQ:OTLK Outlook Therapeutics (OTLK) Stock Price, News & Analysis → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free OTLK Stock Alerts $7.78 -0.46 (-5.58%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$7.31▼$8.4250-Day Range$5.73▼$9.7052-Week Range$4.00▼$40.60Volume414,209 shsAverage Volume157,916 shsMarket Capitalization$101.28 millionP/E RatioN/ADividend YieldN/APrice Target$47.34 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Outlook Therapeutics alerts: Email Address Outlook Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside508.1% Upside$47.34 Price TargetShort InterestHealthy7.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 21 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.75) to ($2.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector488th out of 947 stocksBiological Products, Except Diagnostic Industry81st out of 159 stocks 4.4 Analyst's Opinion Consensus RatingOutlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.34, Outlook Therapeutics has a forecasted upside of 508.1% from its current price of $7.79.Amount of Analyst CoverageOutlook Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.89% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Outlook Therapeutics has recently decreased by 11.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOutlook Therapeutics does not currently pay a dividend.Dividend GrowthOutlook Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OTLK. Previous Next 2.4 News and Social Media Coverage News SentimentOutlook Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Outlook Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows14 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Outlook Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Outlook Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Outlook Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Outlook Therapeutics are expected to grow in the coming year, from ($3.75) to ($2.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Outlook Therapeutics is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Outlook Therapeutics is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Outlook Therapeutics Stock (NASDAQ:OTLK)Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Read More OTLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OTLK Stock News HeadlinesMarch 18, 2024 | globenewswire.comOutlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionMarch 18, 2024 | finance.yahoo.comGlobal Sustainable Packaging Market Outlook & Forecast 2024-2029: Biodegradable Innovations and E-Commerce Driving GrowthMarch 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.March 18, 2024 | americanbankingnews.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) to Post Q2 2024 Earnings of ($1.28) Per Share, Brookline Capital Management ForecastsMarch 17, 2024 | markets.businessinsider.comBITmarkets' New Crypto Outlook Adresses Bitcoin Halving and Other Milestones of 2024March 17, 2024 | americanbankingnews.comOutlook Therapeutics (NASDAQ:OTLK) Trading 5.4% Higher March 14, 2024 | uk.finance.yahoo.com2024 Automotive Tapes Market Outlook Report: Industry Size, Market Shares Data, Insights, Growth Trends, Opportunities, Competition 2023 to 2031March 14, 2024 | markets.businessinsider.comEQS-News: Management Board Gives Positive Outlook for FY 2023/2024March 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 14, 2024 | sg.finance.yahoo.comOutlook Therapeutics Inc (41ON.MU)March 13, 2024 | msn.comThe end of classic Outlook for Windows is coming. Are you ready?March 13, 2024 | msn.comOutlook Therapeutics falls on 1-for-20 reverse stock splitMarch 12, 2024 | msn.comHow to add emojis in OutlookMarch 12, 2024 | globenewswire.comOutlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitMarch 11, 2024 | businesswire.comGlobal Yacht Market Outlook 2024-2029: Emerging Players from Asia-Pacific Making Waves as Europe Holds the Dominant Spot - ResearchAndMarkets.comMarch 6, 2024 | investorplace.com7 of the Best Speculative Stocks You Can Snag for Less Than $1February 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 20, 2024 | msn.comHow to add Outlook Calendar to Google CalendarFebruary 19, 2024 | news.yahoo.comSam's Oscar Outlook: Best Costume DesignFebruary 16, 2024 | finanznachrichten.deOutlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateFebruary 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Outlook Therapeutics Amidst Promising Market Prospects for ONS-5010/LytenavaFebruary 16, 2024 | msn.comOutlook Therapeutics stock climbs 13% amid Chardan upgradeFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Outlook Therapeutics on Strategic Progress and Strong Financial PositioningFebruary 14, 2024 | finance.yahoo.comOutlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic DevelopmentsFebruary 14, 2024 | finance.yahoo.comOutlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateFebruary 14, 2024 | globenewswire.comOutlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateFebruary 6, 2024 | investing.comOUTLOOK THERAPEUTICS INC (OTLK)See More Headlines Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/18/2024Next Earnings (Estimated)5/20/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OTLK CUSIPN/A CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Target$47.34 High Stock Price Target$100.00 Low Stock Price Target$20.00 Potential Upside/Downside+508.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,741.39% Return on Assets-132.37% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-7.01Miscellaneous Outstanding Shares13,010,000Free Float12,323,000Market Cap$101.28 million OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ralph H. Thurman (Age 75)Independent Executive Chairman Comp: $207.5kMr. C. Russell Trenary III (Age 66)President, CEO & Director Comp: $610.9kMr. Lawrence A. Kenyon CPA (Age 58)Executive VP, CFO, Treasurer, Company Secretary & Director Mr. Jeffrey Evanson (Age 55)Chief Commercial Officer Comp: $451.17kMs. Alicia TozierSenior Vice President, Marketing & Market AccessMr. Joel PrieveSenior Vice President of Licensing and M&ADr. Surendra Sharma M.D.Senior Vice President of Medical AffairsDr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory AffairsMr. Jedd ComiskeySenior VP - Head of EuropeMore ExecutivesKey CompetitorsaTyr PharmaNASDAQ:LIFEAthira PharmaNASDAQ:ATHAAlloVirNASDAQ:ALVRCardiol TherapeuticsNASDAQ:CRDLProtalix BioTherapeuticsNYSE:PLXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 277,326 shares on 3/11/2024Ownership: 2.521%Virtu Financial LLCBought 68,146 shares on 2/26/2024Ownership: 0.026%Vanguard Group Inc.Bought 277,326 shares on 2/15/2024Ownership: 2.521%Barclays PLCBought 188,952 shares on 2/15/2024Ownership: 0.083%Northern Trust CorpBought 117,314 shares on 2/13/2024Ownership: 0.528%View All Insider TransactionsView All Institutional Transactions OTLK Stock Analysis - Frequently Asked Questions Should I buy or sell Outlook Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OTLK shares. View OTLK analyst ratings or view top-rated stocks. What is Outlook Therapeutics' stock price target for 2024? 8 brokers have issued 12-month price targets for Outlook Therapeutics' shares. Their OTLK share price targets range from $20.00 to $100.00. On average, they expect the company's share price to reach $47.34 in the next twelve months. This suggests a possible upside of 508.1% from the stock's current price. View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts. How have OTLK shares performed in 2024? Outlook Therapeutics' stock was trading at $7.88 at the beginning of 2024. Since then, OTLK shares have decreased by 1.2% and is now trading at $7.7850. View the best growth stocks for 2024 here. When is Outlook Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our OTLK earnings forecast. How were Outlook Therapeutics' earnings last quarter? Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.20. When did Outlook Therapeutics' stock split? Shares of Outlook Therapeutics reverse split on Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Outlook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX). Who are Outlook Therapeutics' major shareholders? Outlook Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.52%), Vanguard Group Inc. (2.52%), Northern Trust Corp (0.53%), Scotia Capital Inc. (0.11%), Barclays PLC (0.08%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include C Russell Trenary III, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Terry Dagnon and Yezan Munther Haddadin. View institutional ownership trends. How do I buy shares of Outlook Therapeutics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OTLK) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThey said crypto was dead. It went up 100X.InvestorPlaceMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.